Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype

被引:469
作者
Breems, Dimitri A.
Van Putten, Wim L. J.
De Greef, Georgine E.
Van Zelderen-Bhola, Shama L.
Gerssen-Schoorl, Klasien B. J.
Mellink, Clemens H. M.
Nieuwint, Aggie
Jotterand, Martine
Hagemeijer, Anne
Beverloo, H. Berna
Lowenberg, Bob [1 ]
机构
[1] Erasmus Univ, Med Ctr, Dept Hematol, NL-3000 CA Rotterdam, Netherlands
关键词
D O I
10.1200/JCO.2008.16.0259
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To investigate the prognostic value of various cytogenetic components of a complex karyotype in acute myeloid leukemia (AML). Patients and Methods Cytogenetics and overall survival (OS) were analyzed in 1,975 AML patients age 15 to 60 years. Results Besides AML with normal cytogenetics (CN) and core binding factor (CBF) abnormalities, we distinguished 733 patients with cytogenetic abnormalities. Among the latter subgroup, loss of a single chromosome (n = 109) conferred negative prognostic impact (4-year OS, 12%; poor outcome). Loss of chromosome 7 was most common, but outcome of AML patients with single monosomy -7 (n = 63; 4- year OS, 13%) and other single autosomal monosomies (n = 46; 4-year OS, 12%) did not differ. Structural chromosomal abnormalities influenced prognosis only in association with a single autosomal monosomy (4-year OS, 4% for very poor v 24% for poor). We derived a monosomal karyotype (MK) as a predictor for very poor prognosis of AML that refers to two or more distinct autosomal chromosome monosomies (n = 116; 4-year OS, 3%) or one single autosomal monosomy in the presence of structural abnormalities (n = 68; 4-year OS, 4%). In direct comparisons, MK provides significantly better prognostic prediction than the traditionally defined complex karyotype, which considers any three or more or five or more clonal cytogenetic abnormalities, and also than various individual specific cytogenetic abnormalities (eg, del[5q], inv[3]/t[3; 3]) associated with very poor outcome. Conclusion MK enables (in addition to CN and CBF) the prognostic classification of two new aggregates of cytogenetically abnormal AML, the unfavorable risk MK-negative category (4-year OS, 26% +/- 2%) and the highly unfavorable risk MK-positive category (4- year OS, 4% +/- %).
引用
收藏
页码:4791 / 4797
页数:7
相关论文
共 14 条
  • [1] Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission:: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial
    Breems, DA
    Boogaerts, MA
    Dekker, AW
    Van Putten, WLJ
    Sonneveld, P
    Huijgens, PC
    Van der Lelie, J
    Vellenga, E
    Gratwohl, A
    Verhoef, GEG
    Verdonck, LF
    Löwenberg, B
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (01) : 59 - 65
  • [2] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
    Byrd, JC
    Mrózek, K
    Dodge, RK
    Carroll, AJ
    Edwards, CG
    Arthur, DC
    Pettenati, MJ
    Patil, SR
    Rao, KW
    Watson, MS
    Koduru, PRK
    Moore, JO
    Stone, RM
    Mayer, RJ
    Feldman, EJ
    Davey, FR
    Schiffer, CA
    Larson, RA
    Bloomfield, CD
    [J]. BLOOD, 2002, 100 (13) : 4325 - 4336
  • [3] Farag SS, 2002, INT J ONCOL, V21, P1041
  • [4] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
    Grimwade, D
    Walker, H
    Oliver, F
    Wheatley, K
    Harrison, C
    Harrison, G
    Rees, J
    Hann, I
    Stevens, R
    Burnett, A
    Goldstone, A
    [J]. BLOOD, 1998, 92 (07) : 2322 - 2333
  • [5] Lowenberg B, 1997, J CLIN ONCOL, V15, P3496
  • [6] Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
    Löwenberg, B
    van Putten, W
    Theobald, M
    Gmür, J
    Verdonck, L
    Sonneveld, P
    Fey, M
    Schouten, H
    de Greef, G
    Ferrant, A
    Kovacsovics, T
    Gratwohl, A
    Daenen, S
    Huijgens, P
    Boogaerts, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (08) : 743 - 752
  • [7] Prognostic factors in acute myeloid leukaemia
    Löwenberg, B
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (01) : 65 - 75
  • [8] Mitelman F, 1995, ICSN 1995 INT SYSTEM
  • [9] Cytogenetics in acute leukemia
    Mrózek, K
    Heerema, NA
    Bloomfield, CD
    [J]. BLOOD REVIEWS, 2004, 18 (02) : 115 - 136
  • [10] Mrozek Krzysztof, 2006, Hematology Am Soc Hematol Educ Program, P169